Episode
Quantum Computing Is Becoming a Drug Repurposing Engine
- Published
- Jun 19, 2026
- Duration seconds
- 586
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/episodes/quantum-computing-is-becoming-a-drug-repurposing-engine/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/quantum-computing-business-with-fexingo-hardware-software-and-enterprise-quantum-7872009/quantum-computing-is-becoming-a-drug-repurposing-engine.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Quantum Computing Business with Fexingo, Lucas and Luna explore how quantum computers are accelerating drug repurposing — finding new uses for existing drugs. They dig into a specific case: a 2025 collaboration between pharmaceutical giant Pfizer and quantum startup 1QBit. Using a quantum-classical hybrid algorithm running on D-Wave's Advantage system, the team screened 2,100 existing compounds against a target protein linked to a rare autoimmune disorder. They identified 14 promising candidates in under 6 hours — something that would have taken weeks on classical supercomputers. Lucas breaks down how the algorithm works, why repurposing is cheaper than de novo drug discovery, and what this means for the economics of the $1.4 trillion pharmaceutical industry. Luna challenges him on whether the results are reproducible at scale. The episode also touches on the broader trend of quantum annealing versus gate-based quantum computing in pharma, and where the field stands as of mid-2026. #QuantumComputing #DrugRepurposing #Pfizer #1QBit #DWave #Pharmaceuticals #RareDisease #QuantumAnnealing #DrugDiscovery #HybridQuantum #Business #Technology #Biotech #AI #MachineLearning #FexingoBusiness #BusinessPodcast #HealthcareInnovation Keep every episode free: buymeacoffee.com/fexingo